At Evolve, we are firm believers in the transformative potential of cell & gene therapies for patients. We are passionate about enabling the transition from vision to reality through robust IP strategies that build upon the incredible science behind these technologies.
In this webinar we will provide practical and commercially focused IP insights based on our considerable industry and transactional experience in the sector.
Topics covered:
- How cell & gene therapy companies can build a robust and effective IP strategy that is attractive to investors and potential partners.
- IP considerations for successful deal-making in cell & gene therapy, including tips and tricks for effective negotiations.
- How to approach IP due diligence for cell & gene therapy companies, including freedom to operate, patentability and the risk of design-around.
- Real-life case studies.
Who should attend:
- Investors, business leaders and business development professionals in the cell & gene therapy sector.
- Tech transfer professionals working with cell & gene therapy technologies.
- In-house IP counsel working with cell & gene therapy technologies.
- Anyone interested in commercialisation strategy for cell & gene therapies.
Speakers: Rose Hughes and Steven Gurney
Chair: Claudia Greaves
Rose has extensive industry experience leading the IP strategy for cell & gene therapy technologies, including platform development and clinical stage products. In her former role as Patent Director at At AstraZeneca, Rose also lead the IP negotiations for high-profile deals in the sector. With a PhD in immunology from UCL, Rose is still an immunologist at heart and passionate about providing cell & gene therapy companies with the IP guidance they need to succeed.
Steven is focused on maximising the potential of his pharmaceutical and life science clients. As the founder of Evolve Intellectual Property in 2021, he brings a passion for developing robust IP strategies and providing expert counsel. Steven’s expertise spans pharmaceuticals, drug development and IP, drafting, portfolio management and prosecution, lifecycle management, licensing (in- and out-), due diligence and FTO, contentious work (including litigation and opposition), and regulatory exclusivities like PTE/SPC.
See our blog for more cell & gene therapy IP insights.